Recent Updates
Recently added Catalysts
BIO Positive Sentiment

Bio-Rad Reports Third-Quarter 2026 Financial Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bio-Rad Laboratories reported its third-quarter financial results for 2026, indicating a return to currency-neutral revenue growth. The growth was primarily driven by the Clinical Diagnostics segment and strong demand for Droplet Digital products. CEO Norman Schwartz highlighted the company's steady progress during this period.

Market Sentiment Analysis

POSITIVE FACTORS

  • Returned to currency-neutral revenue growth.
  • Strong demand for Droplet Digital products.
  • Positive financial results for third quarter.

Full Press Release Details

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026. Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™

Frequently Asked Questions

What were Bio-Rad's Q3 2026 financial results?

Bio-Rad reported a return to currency-neutral revenue growth in Q3 2026.

What drove Bio-Rad's revenue growth?

The growth was led by Clinical Diagnostics and demand for Droplet Digital products.

Who is the CEO of Bio-Rad?

Norman Schwartz is the Chief Executive Officer of Bio-Rad.

When did Bio-Rad report its Q3 results?

Bio-Rad announced its Q3 results for the period ending September 30, 2026.

ShareAdd on Google
Tags: BIO Bio-Rad financial results Q3 2026 Clinical Diagnostics Droplet Digital
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$1619M liquidity · $0M/mo burn
Low dilution risk